Table 3.
Correlation analysis of FOXP3 polymorphisms in relation to prognostic parameters in total BC sample and aggressive subtypes.
| Clinical outcomes | Total BC p (tau) |
Breast cancer subtypes [p (tau)] | |||
|---|---|---|---|---|---|
| LB | HER2+ | TN | |||
| g.10403A>G | TNM staging | 0.173 (τ = 0.11) | 0.608 (τ = 0.08) | 0.835 (τ = −0.04) | 0.032 (τ = 0.23)∗ |
| Tumor size | 0.633 (τ = −0.04) | 0.885 (τ = 0.02) | 0.778 (τ = 0.05) | 0.422 (τ = −0.10) | |
| Ki-67 | 0.270 (τ = 0,11) | 0.837 (τ = 0.04) | 0.019 (τ = 0.47)∗ | 0.536 (τ = 0.08) | |
| Histological grade | 0.268 (τ = −0.10) | 0.846 (τ = −0.03) | 0.061(τ = −0.36) | 0.909 (τ = −0.02) | |
| LP commitment | 0.298 (τ = 0.09) | 0.337 (τ = 0.15) | 0.175(τ = 0.255) | 0.934 (τ = −0.01) | |
|
| |||||
| g.8048A>C | TNM staging | 0.966 (τ = −0.003) | 0.894 (τ = 0.02) | 0.167 (τ = 0.23) | 0.084(τ = −0.23) |
| Tumor size | 0.166 (τ = 0.10) | 0.403 (τ = 0.11) | 0.912 (τ = −0.02) | 0.419(τ = 0.10) | |
| Ki-67 | 0.557 (τ = −0.06) | 0.28 (τ = −0.21) | 0.018 (τ = −0.47)∗ | 0.708 (τ = 0.05) | |
| Histological grade | 0.135 (τ = −0.15) | 0.754 (τ = 0.06) | 0.026 (τ = 0.39)∗ | 0.927 (τ = 0.01) | |
| LP commitment | 0.895 (τ = −0.01) | 0.662 (τ = −0.07) | 0.811(τ = −0.05) | 0.913 (τ = 0.02) | |
Kendall's tau test; ∗value of p < 0.05 was considered statistically significant. BC: breast cancer; LB: Luminal B HER2+; HER2+: HER2-enriched; TN: triple-negative; LP: lymph node.